3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase 3
1
Status
Recruiting
3
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Tumor-Agnostic
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Brain Neoplasms
4
Neoplasms
3
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms, Unknown Primary
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
35
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
23
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Docetaxel
19
Oxaliplatin
18
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Ipilimumab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasms
×
entrectinib
×
1 year
×
Clear all
NCT05862285
2026-05-12
UmbrellaMAX
Hoffmann-La Roche
Phase 3
Recruiting
100 enrolled
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled